(AIM) AIM ImmunoTech - Ratings and Ratios

Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00901B1052

AIM: Immuno-Therapeutics, RNA Drug, Interferon, Cancer Treatment

AIM ImmunoTech Inc. (NYSE MKT: AIM) is a biotechnology company specializing in the development of immunotherapeutic drugs. The companys primary focus is on creating treatments for various cancers, viral infections, and immune system disorders. Its lead product, Ampligen, is a ribonucleic acid (RNA) molecule under investigation for chronic fatigue syndrome (CFS), pancreatic cancer, renal cell carcinoma, melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, and prostate cancer. Ampligen is also being studied for myalgic encephalomyelitis (ME), Hepatitis B, HIV, COVID-19, and post-COVID conditions. Additionally, the company offers Alferon N Injection, an alpha interferon treatment for human papillomavirus (HPV) and genital warts. AIM ImmunoTech has established collaborations with several research institutions and pharmaceutical companies, including Amarex Clinical Research, University of Cagliari, and Erasmus University Medical Center. Formerly known as Hemispherx Biopharma, the company rebranded as AIM ImmunoTech in August 2019. Founded in 1966, it is headquartered in Ocala, Florida.

Based on the provided and , the 3-month forecast for AIM ImmunoTech Inc. (NYSE MKT: AIM) suggests cautious optimism. The stocks average volume of 981,416 shares over 20 days indicates moderate liquidity. The last price of $0.13 is below the SMA 20 ($0.14) and SMA 50 ($0.18), signaling potential near-term weakness. However, the SMA 200 of $0.27 suggests that the stock may rebound if it can surpass the SMA 50 resistance level. The ATR of $0.02 reflects low volatility, which could stabilize price movements. On the fundamental side, the market cap of $9.14M and P/S ratio of 48.13 highlight the companys speculative nature and reliance on future growth prospects. With a P/B ratio of 3.17, the stock is trading above its book value, indicating investor confidence in its pipeline. Overall, the stock is likely to remain volatile, with potential upside if Ampligens clinical trials show positive results.

Additional Sources for AIM Stock

AIM Stock Overview

Market Cap in USD 9m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 1996-07-12

AIM Stock Ratings

Growth 5y -97.4%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -62.4
Analysts 4.5/5
Fair Price Momentum 0.06 USD
Fair Price DCF -

AIM Dividends

No Dividends Paid

AIM Growth Ratios

Growth Correlation 3m -81.6%
Growth Correlation 12m -95.8%
Growth Correlation 5y -95.2%
CAGR 5y -44.53%
CAGR/Max DD 5y -0.46
Sharpe Ratio 12m -1.61
Alpha -77.12
Beta 1.19
Volatility 95.64%
Current Volume 509.5k
Average Volume 20d 711.7k
What is the price of AIM stocks?
As of March 16, 2025, the stock is trading at USD 0.12 with a total of 509,484 shares traded.
Over the past week, the price has changed by -12.78%, over one month by -10.08%, over three months by -44.76% and over the past year by -65.22%.
Is AIM ImmunoTech a good stock to buy?
No, based on ValueRay Analyses, AIM ImmunoTech (NYSE MKT:AIM) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -97.38 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AIM as of March 2025 is 0.06. This means that AIM is currently overvalued and has a potential downside of -50%.
Is AIM a buy, sell or hold?
AIM ImmunoTech has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy AIM.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for AIM stock price target?
According to ValueRays Forecast Model, AIM AIM ImmunoTech will be worth about 0.1 in March 2026. The stock is currently trading at 0.12. This means that the stock has a potential downside of -50%.
Issuer Forecast Upside
Wallstreet Target Price 2.8 2191.7%
Analysts Target Price 2.8 2191.7%
ValueRay Target Price 0.1 -50%